Related Experiment Video
Updated: Jul 22, 2025

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
Thyrotoxic Periodic Paralysis With Hypokalemia: A Case Study.
Nova B Mebane1, Aisha Khan1, Manzoor Bevinal1
1Internal Medicine, Corpus Christi Medical Center, Corpus Christi, USA.
Thyrotoxic periodic paralysis (TPP) is a rare condition causing paralysis, often triggered by high-carbohydrate meals or steroid injections. This case highlights TPP in a young male with new-onset hyperthyroidism and hypokalemia.
Area of Science:
- Endocrinology
- Neurology
Background:
- Thyrotoxic periodic paralysis (TPP) is a rare, life-threatening disorder.
- It predominantly affects young adults (20-40 years), particularly Hispanic and Asian populations.
Observation:
- A case report of a young male patient presenting with acute paralysis.
- The patient exhibited new-onset hyperthyroidism and severe hypokalemia.
Findings:
- TPP symptoms were triggered by a high-carbohydrate meal.
- A steroid injection also exacerbated the patient's paralysis within 24 hours of onset.
Implications:
- This case underscores the importance of recognizing TPP triggers in susceptible individuals.
- Prompt diagnosis and management of hyperthyroidism and hypokalemia are crucial for TPP patients.
More Related Videos
08:28Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
04:05Author Spotlight: Accurately Assessing Thyroid Hormone-Driven Motor Alterations in Mouse
Published on: October 6, 2023
Related Concept Videos
Dysrhythmias V: Evaluating Dysrhythmias
Antihypertensive Drugs: Potassium-Sparing Diuretics
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...